Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 2/20 | 0.36 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25319726 | 0.95 | LMNA (0.43) | CA2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL23928465 | 0.89 | CA2 (0.46) | CA2GRIK1GRIK2EPHX2GPR84 | |
| SCHEMBL29180336 | 0.89 | CA2 (0.48) | CA2GRIK1GRIK2EPHX2GPR84 | |
| SCHEMBL26726038 | 0.86 | EPHX2 (0.47) | KDM5APHF8KDM4CEPHX2FFAR1 | |
| SCHEMBL24340301 | 0.85 | CA2 (0.46) | CA2LMNAGRIK1GRIK2GPR84 | |
| SCHEMBL23928464 | 0.85 | EPHX2 (0.41) | CA2TSHREPHX2GPR84FFAR1 | |
| SCHEMBL25317185 | 0.84 | S1PR2 (0.46) | CA2GRIK1GRIK2KDM5APHF8 | |
| SCHEMBL30900227 | 0.83 | NAAA (0.40) | — | |
| SCHEMBL24764590 | 0.83 | CA2 (0.47) | CA2LMNAGRIK1GRIK2EPHX2 | |
| SCHEMBL25698920 | 0.83 | CA2 (0.47) | CA2LMNAGRIK1GRIK2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102260-A1 | CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING ANGIOPOIETIN LIKE 3 (ANGPTL3) | EDITAS MEDICINE, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20250188020-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | ACUITAS THERAPEUTICS INC (CA) | 2025-06-12 | — | — | US | disclosed |
| US-12129223-B2 | Lipids for use in lipid nanoparticle formulations | Acuitas Therapeutics, Inc. (CA) | 2024-10-29 | — | — | US | disclosed |
| EP-4448485-A2 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2024-10-23 | — | — | EP | disclosed |
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-09-21 | — | — | US | disclosed |
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-09-21 | — | — | US | disclosed |
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-09-21 | — | — | US | disclosed |
| WO-2023114943-A2 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | PHOSPHO1, SGMS1, NPC1 | CA2 2604/4885LMNA 196/4885ALDH1A1 1138/4885 |
| US-20250188020-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | PHOSPHO1, SGMS1, NPC1 | CA2 2604/4885LMNA 196/4885ALDH1A1 1138/4885 |
| US-12129223-B2 | Lipids for use in lipid nanoparticle formulations | PHOSPHO1, SGMS1, NPC1 | CA2 2604/4885LMNA 196/4885ALDH1A1 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.